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Abstract
The Sequenom MassARRAY iPLEX single-nucleotide polymorphism (SNP) typing platform uses matrix-assisted laser desorption ioniza-
tion time-of-ﬂight mass spectrometry (MALDI-TOF MS) coupled with single-base extension PCR for high-throughput multiplex SNP
detection. In this study, we investigated the use of iPLEX MassARRAY technology for methicillin-resistant Staphylococcus aureus (MRSA)
genotyping. A 16-plex MassARRAY iPLEX GOLD assay (MRSA-iPLEX) was developed that targets a set of informative SNPs and binary
genes for MRSA characterization. The method was evaluated with 147 MRSA isolates, and the results were compared with those of an
established SYBR Green-based real-time PCR system utilizing the same SNP–binary markers. A total of 2352 markers belonging to 44
SNP–binary proﬁles were analysed by both real-time PCR and MRSA-iPLEX. With real-time PCR as the reference standard, MRSA-
iPLEX correctly assigned 2298 of the 2352 (97.7%) markers. Sequence variation in the MRSA-iPLEX primer targets accounted for the
majority of MRSA-iPLEX erroneous results, highlighting the importance of primer target selection. MRSA-iPLEX provided optimal
throughput for MRSA genotyping, and was, on a reagent basis, more cost-effective than the real-time PCR methods. The 16-plex
MRSA-iPLEX is a suitable alternative to SYBR Green-based real-time PCR typing of major sequence types and clonal complexes of
MRSA.
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Introduction
Infections caused by community-associated methicillin-resis-
tant Staphylococcus aureus (CA-MRSA) and healthcare-associ-
ated methicillin-resistant S. aureus (HA-MRSA) pose a
signiﬁcant problem to healthcare facilities and within the
community, because of their association with signiﬁcant
morbidity and mortality (1–4). CA-MRSA is often linked to
production of the Panton–Valentine leukocidin (PVL) toxin,
which is associated with tissue necrosis and fatal necrotizing
pneumonia (5). The increased prevalence of CA-MRSA and
HA-MRSA worldwide has highlighted the need for accurate
epidemiological surveillance systems (6,7), with methicillin-
resistant S. aureus (MRSA) genotyping now being an integral
part of clinical and health facility management (8,9). Tradi-
tional tools for MRSA epidemiological surveillance include
pulsed-ﬁeld gel electrophoresis (PFGE), multilocus sequence
typing (MLST), staphylococcal cassette chromosome mec
(SCCmec) element typing, and staphylococcal protein A (spa)
sequence typing (10,11). PFGE is highly discriminatory and is
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typically employed for short-term surveillance, whereas
MLST/SCCmec and spa sequencing are used for long-term
surveillance of genetic relatedness (11). Although the results
obtained with these tools are highly reproducible, their limi-
tations include high technical complexity, expense, and pro-
longed result turn-around times (10,11).
More recently, MRSA genotyping based on a set of infor-
mative single-nucleotide polymorphisms (SNPs) and binary
markers has been employed. These methods are effectively
mini-MLSTs, and have proved to have a similar performance
to full MLST data for resolving clonal complexes and certain
sequence types (STs) (10,12), with the added advantage of
using real-time PCR technology for rapid and cost-effective
SNP discrimination with simple data analysis software (13–
15). The MRSA typing method used by our laboratory was
originally described by Huygens et al. (13), and consists of 17
separate SYBR Green-based real-time PCRs, including two
assays to conﬁrm MRSA (mecA and nuc), eight assays to dis-
criminate seven informative SNPs (arcC210, tpi241/243,
arcC162, gmk318, pta294, tpi36*T, tpi36*C, and pta383), ﬁve
assays targeting binary genes (pvl, cna, sdrE, pUB110, and
pT181), one additional SNP assay (aroE252G) for conﬁrma-
tion of the Queensland CA-MRSA ST93, and one internal
control reaction (16S). The method is robust, is able to dis-
cern major Australian and certain international MRSA STs
and clonal complexes (CCs), including the South West Paciﬁc
(SWP) (ST30) and Queensland CA-MRSA (ST93) clones, as
well as the HA-MRSA ST239 clone (colloquially known as
Aus-2 and Aus-3 EMRSA), and has since been employed in
numerous studies (16–18). The limitation of this method is
that throughput can be severely impeded by the number of
individual reactions that need to be performed (17 per iso-
late), particularly in a routine laboratory, where the number
of MRSA isolates is high and valuable space on real-time PCR
instruments may be quickly sequestered by other testing.
The Sequenom (Brisbane, Australia) MassARRAY iPLEX
SNP typing platform uses matrix-assisted laser desorption
ionization time-of-ﬂight mass spectrometry (MALDI-
TOF MS) coupled with single-base extension PCR for high-
throughput multiplex SNP detection, which is capable of mul-
tiplexing up to 40 SNPs per single reaction (19–21). In this
study, we adapted the above MRSA SNP–binary typing
method to the iPLEX system (MRSA-iPLEX). MRSA-iPLEX
was validated with 147 clinical MRSA isolates, and the results
were compared with those of the real-time PCR methods.
Materials and Methods
Bacterial isolates
A total of 147 clinical MRSA isolates were retrospectively
tested with SYBR Green real-time PCR and MRSA-iPLEX.
These included 110 clinical MRSA isolates from previous stud-
ies (15,22), 25 local outbreak isolates (Princess Alexandria
Hospital in 2006, n = 17, and Royal Brisbane Hospital in 2007,
n = 8), and 12 MRSA control isolates used in our laboratory.
Of the 147 isolates, 103 were major STs or CCs (summarized
in Table 1), and the remaining 44 were either minor CCs or
otherwise not assigned. A subset of isolates (n = 68) were
characterized by PFGE, MLST and SCCmec typing, as previ-
ously described (23), and are summarized in Table S1.
Nucleic acid extraction
Isolates were grown on horse blood agar at 37C overnight.
For each isolate, a 1-lL loop of a 24-h colony was suspended in
250 lL of HPLC-grade water and treated with lysostaphin
(40 mg/lL). Nucleic acids were puriﬁed with the Corbett CAS-
1820 X-tractor Gene, following the manufacturer’s instruc-
tions (Qiagen, Doncaster, Australia). The DNA concentration
was determined with the NanoDrop 1000 (Thermo Fisher Sci-
entiﬁc, Scoresby, Australia), and this was followed by dilution
to a ﬁnal concentration of 5 ng/lL. Diluted extracts were used
immediately or stored at )20C until further analysis.
MRSA detection, typing and analysis with SYBR Green real-
time PCR
The SYBR Green real-time PCR assays were performed and
analysed as previously described (13). For conﬁrmatory and
binary assays, a positive or negative result was coded as one
or zero. SNP assay results (arcC210, tpi241/3, arcC162,
TABLE 1. Major sequence types
(STs) or clonal complex (CC) pro-
ﬁles of methicillin-resistant Staphy-
lococcus aureus (MRSA) isolates
CC or ST
complex SNP proﬁlea
No. of
isolates Included PFGE types
1 CGATAACT/TGATTACT 10 WA-MRSA-10, WA-MRSA-38, WA-MRSA-60
5 CGATTACA 22 WA-MRSA-3, WA-MRSA-11, Mu50
8 TGATACCA 18 USA300, Irish EMRSA-1
30 TGGATCCA 8 PAH58, WSPP MRSA
93 TGGTTCTA 8 QLD, RBH98
239 TGAAACCA 37 AUS EMRSA-2, AUS EMRSA-3
PFGE, pulsed-ﬁeld gel electrophoresis; SNP, single-nucleotide polymorphism.
aSNP results in the order arcC210, tpi241 + 243, arcC162, gmk318, pta294, tpi36, and pta383.
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gmk318, pta294, tpi36, and pta383) were coded as G, C A,
or T. For the aroE252 assay, the conﬁrmatory assay for the
Queensland clone ST93, positive results were coded as G.
MRSA detection and typing with MassARRAY MALDI-
TOF MS (MRSA-iPLEX)
MRSA-iPLEX design. Sequence data available on the NCBI/
GenBank/UCSC Gene Browser and S. aureus MLST database
(http://www.mlst.net) were utilized. Optimal ampliﬁcation
primers and extension primers for use in a multiplex format
were designed with Assay Designer v3.1 (Sequenom). Prim-
ers were supplied by Sigma Genosys (Castle, Hill, Australia),
and contained the 5¢ 10mer extension (ACGTTGGATG) to
remove them from the observed mass window and provide
stability in a multiplex PCR reaction. PCR and extension
primers for multiplex MRSA typing are listed in Tables 2
and 3. PCR primers were mixed equimolar at 1.0 lM, and
the extension primer mix was prepared by dividing primers
into two groups on the basis of mass, and diluting the high-
mass primers to 14.0 lM and the low-mass primers to
9.0 lM. The extension primer adjustment was ﬁne tuned
with MALDI-TOF MS and Typer 4 to ensure that all prim-
ers were present in the mix and that peak intensities were
equalized.
Primary PCR reaction and shrimp alkaline phosphatase (SAP)
treatment. The PCR multiplex assay was performed on the
GeneAMP PCR system 9700 (Applied Biosystems, Mulgrave,
Australia), with the Sequenom PCR Reagent Set. Each reac-
tion contained 1 · PCR Buffer, each primer at 0.1 lM
(Table 2), 4 mM MgCl2, 500 lM dNTP mix, 0.5 units of PCR
enzyme, and 10 ng of DNA template. The ﬁnal reaction vol-
ume was adjusted to 5.0 lL with HPLC-grade water. Samples
and reaction mix were loaded into a 384-well microplate
(Thermo Fisher Scientiﬁc). PCR parameters included an ini-
tial denaturation at 95C for 2 min, 25 cycles of 95C for
30 s, 56C for 30 s, and 72C for 60 s, and a ﬁnal extension
at 72C for 5 min. Each run included negative controls
(water and human DNA), and all samples were tested in
duplicate. Non-incorporated dNTPs were dephosphorylated
by adding 2.0 lL of SAP cocktail (Sequenom), consisting of
0.5 units of SAP enzyme, to the PCR reaction mix, and incu-
bated on the GeneAMP PCR system 9700 at 37C for
40 min, and then at by 85C for 5 min.
TABLE 2. Primers for primary PCR
reaction
Gene
target Forward primera Reverse primera
Amplicon
size (bp)
16S 10mer-GAGATATGGAGGAACACCAG 10mer-TGTTTGATCCCCACGCTTTC 102
nuc 10mer-AGAGTTGTGGATGGTGATAC 10mer-TTCGGTTTCACCGTTTCTGG 118
mecA 10mer-GCTTTGGTCTTTCTGCATTC 10mer-AAGAAGATGGTATGTGGAAG 91
arcC210 10mer-ATAGTGATAGAACTGTAGGC 10mer-CTTTCGTATAAAAAGGACCA 125
tpi241/3 10mer-GCAATCGGAACTGGTAAATC 10mer-CGAGTTGCTTCTGATACTTC 130
gmk318 10mer-GAAGGTGCAAAGCAAGTTAG 10mer-CCTCTACCTACTAATCGCTC 121
pta294 10mer-GTTAGTGGTGCAGCACATTC 10mer-GGATTGATTGCACAATCACC 169
tpi36 10mer-CACGAAACAGATGAAGAAA 10mer-ACGCTCTTCGTCTGTTTCAC 116
pvl 10mer-GGCTATACAAAGCCAAATCC 10mer-AATGTTGTACTTAGAACCCC 89
cn 10mer-TGATGTTTCGGGATTTGCAG 10mer-TTCCCAGATGTTATCGTAGC 116
sdr 10mer-TACGAAGATGTAACAAGTC 10mer-AGTTCGCCATCTGATGTAGG 157
pUB110 10mer-CGTGATGGAAAACTGCAAGG 10mer-ACCACGCTCCAACTCAAAAC 131
pT181 10mer-TGAGCTGTCTTGGTTCATTG 10mer-AATGCAGCAGATCCTACTCC 117
aroE252 10mer-GTCTGGATAAACGCTGTGCAA 10mer-GTGGATAGGGTATAATACAG 83
a10mer = 10-mer tag ACGTTGGATG placed at 5¢-end of each primer.
TABLE 3. Primers and masses for
ASPE reaction
Target UEP EP1a (Da) EP2a (Da) EP3 (Da)
16S gctAAGGCGACTTTCTGGTCTG 6757.4 A, 7028.6 T, 7084.5
nuc gAAAGAAATTAAAGTTAGGCTTATAG 8090.3 G, 8377.5 T, 8417.4
mecA TGGAAGTTAGATTGGGAT 5633.7 G, 5880.9 C, 5920.9
arcC210 gggagAAAAAGGACCAATTGGTTT 7489.9 T, 7761.1 C, 7777.1
tpi241/3 ccCATCAACATCTGAAGATGC 6359.2 GA, 6630.4 GG, 6646.4
arcC162 ACTGTAGGCACAATCGT 5194.4 A, 5465.6 T, 5521.5
gmk318 ATCGCTCTCTCAAGTG 4832.2 T, 5103.4 A, 5159.3
pta294 cccCAGCACATTCAACAGG 5726.7 C, 5973.9 A, 5998
tpi36 gggtAAATTAACAAAAAAGCGCA 7122.7 C, 7369.9 T, 7449.8
pta383 ATCTTCTTTATGATTAAAGGTGATG 7701 A, 7972.2 T, 8028.1
pvl cccGTACTTAGAACCCCAATAAAAT 7563 T, 7834.2 A, 7890.1
can TAGCTACTTTGTCATCTGA 5768.8 T, 6040 A, 6095.9
sdrE gggcATATCACCAAAATCCAATGT 7329.8 T, 7601 A, 7656.9
pUB110 CGTCAAGAACTGTTATGGCT 6132 A, 6403.2 T, 6459.1
pT181 AACCTACCAAAAATCAAAATAAAAAA 7934.3 G, 8181.4 C, 8221.5
aroE252
T, 6843.3
gACAGATGGTATCGGTTATGT 6516.2 A, 6787.5 G, 6803.5
aEP1 denotes a positive result and EP2 a negative result for binary and conﬁrmatory genes.
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iPLEX reaction and ﬁnal cleanup. The single-base extension
reaction was performed on the GeneAMP PCR system 9700
with the iPLEX Gold Reaction Kit, following the manufac-
turer’s instructions (Sequenom). Brieﬂy, 2.0 lL of the iPLEX
extension primer cocktail, consisting of 0.2 lL of iPLEX Buf-
fer, 0.25 lL of iPLEX Terminator Mix, 0.05 lL of iPLEX
Enzyme, and 0.94 lL of the adjusted iPLEX extension primer
mix (Table 3), was added to each reaction well. PCR condi-
tions included an initial incubation at 94C for 30 s, followed
by 40 cycles of one step at 94C for 5 s with ﬁve subcycles
of 52C for 5 s and 80C for 5s, and a ﬁnal extension at
7C for 3 min. Each extension product was conditioned with
6 mg of CLEAN Resin (Sequenom) and 16 lL of HPLC-grade
water. The microplate was rotated for 15 min, and then cen-
trifuged at 500 g for 5 min with a standard plate centrifuge.
Approximately 10 nL of product was dispensed onto a 384-
format SpectroCHIP (Sequenom), with the MassARRAY
Nanodispenser RS 1000 (Sequenom).
MassARRAY analysis and data quality control. MALDI-TOF MS
analysis was performed on a MassARRAY Compact Analyzer
(Sequenom). Data acquisition was automatically performed
by the use of SpectroAcquire, with ten laser shots per raster
position and a threshold of ﬁve good spectra per sample
pad. The mass window of analyte peak observation was set
at 4500–9000 Da. The data were analysed with Sequenom’s
MassARRAY Typer software version 4.0.3. Genotyping calls
were viewed in call cluster plots, and peak intensities were
reviewed in each respective sample spectrum. Genotyping
calls were considered to be ﬁnal if results between dupli-
cates were concordant. SNP and binary markers were coded
as per the real-time PCR assays, except that results of the
aroE252 assay, the conﬁrmatory assay for ST93, were further
distinguished into either a T or an A base.
Sequence analysis of discrepant results
DNA sequencing was used to investigate representative
markers providing discrepant results between SYBR Green
real-time PCR and MRSA-iPLEX. Primers for DNA sequenc-
ing were developed to encompass both real-time PCR and
MRSA-iPLEX primer target sites (data not shown). PCR
products were submitted to the Australian Genome
Research Facility, St Lucia, Queensland, for DNA sequencing.
Results
A total of 2352 markers belonging to 44 SNP–binary proﬁles
were analysed by both real-time PCR and MRSA-iPLEX, and
are summarized in Table 4 (all 147 isolates) and Table S1
(the subset of 68 isolates). With the real-time PCR as the
reference standard, MRSA-iPLEX correctly assigned 2298 of
the 2352 (97.7%) markers, providing an overall error rate of
2.3% (54/2352). Among the 147 isolates examined, MRSA-
iPLEX correctly identiﬁed all 16 markers for 124 isolates.
There were 23 isolates that accounted for the 54 incor-
rect/failed MRSA-iPLEX results. Of these, 16 were repre-
sented by only three SNP–binary proﬁles, including CC9
(n = 3), ST93 (n = 7), and an unassigned group (n = 6), with
the latter six isolates accounting for 36 of 54 incorrect/failed
results.
TABLE 4. SYBR Green real-time PCR and MRSA-iPLEX
results. Erroneous MRSA-iPLEX proﬁles are denoted by an
‘X’ and discrepant results are in bold italics
No. of
isolates CC/ST SYBR real-time PCRa MRSA-iPLEXa
1 15 111CGATAACA01100 111CGATAACA01100T
1 15 111CGATAACA11100 111CGATAACA11100T
4 1 111CGATAACT01100 111CGATAACT01100T
5 1 111CGATAACT11100 111CGATAACT11100T
1 NAb 111CGATACCA00101 111CGATACCA00001T X
1 NAb 111CGATACCA00000 111CGATACCA00000T
14 5 111CGATTACA00100 111CGATTACA00100T
4 5 111CGATTACA00110 111CGATTACA00110T
2 5 111CGATTACA00101 111CGATTACA00101T
2 5 111CGATTACA11100 111CGATTACA11100T
1 72 111CGATTCCA10100 111CGATTCCA10100T
1 45 111CGGATCCA01100 111CGGATCCA01100A
1 45 111CGGATCCA01100 111CGGATCCA01000A X
2 80 111CGGTACCA10101 111CGGTACCA10101T
1 80 111CGGTACCA10100 111CGGTACCA10100T
2 22 111CGGTTACA01100 111CGGTTACA01100T
1 509 111CGGTTCCA01000 111CGGTTCCA01000T
1 509 111CGGTTCCA01100 111CGGTTCCA01100T
20 239 111TGAAACCA01100 111TGAAACCA01100T
12 239 111TGAAACCA01110 111TGAAACCA01110T
2 239 111TGAAACCA01110 101TGAAACCA01110T X
1 239 111TGAAACCA01101 111TGAAACCA01101T
1 239 111TGAAACCA01010 111TGAAACCA01010T
1 239 111TGAAACCA11110 111TGAAACCA11110T
9 8 111TGATACCA00100 111TGATACCA00100T
1 8 111TGATACCA00100 111TGATACA00100T X
3 8 111TGATACCA00101 111TGATACCA00101T
1 8 111TGATACCA00010 111TGATACCA00010T
2 8 111TGATACCA10101 111TGATACCA10101T
3 8 111TGATACCA10100 111TGATACCA10100T
4 78 111TGATTACA00100 111TGATTACA00100T
1 7 111TGATTACA01100 111TGATTACA01100T
1 1 111TGATTACT01100 111TGATTACT01100T
1 30 111TGGATCCA01000 111TATCCA01000T X
1 30 111TGGATCCA01010 111TGGATCCA01010T
5 30 111TGGATCCA11000 111TGGATCCA11000T
1 30 111TGGATCCA11100 111TGGATCCA11100T
1 NAb 111TGGTAACA11100 111TGGTAACA11100T
1 97 111TGGTAACT00100 111TGGTAACT00100T
1 OCC 111TGGTACCA01100 111TGGTACCA01100T
6 NAb 111TGGTTCCA00100 101GG-TA00000T X
7 59, 121, 133 111TGGTTCTA00100 111TGGTTCTA00100T
1 59, 121, 133 111TGGTTCTA01100 111TGGTTCTA01000A X
3 59, 121, 133 111TGGTTCTA10101 111TGGTTCTA10101T
2 59, 121, 133 111TGGTTCTA10100 111TGGTTCTA10100T
7 93 111TGGTTCTA10100G 101TGGTTCTA10100G X
1 93 111TGGTTCTA11100G 111TGGTTCTA11100G
3 9 111TGATAACT00100 111TGATAACT00000T X
CC, clonal complex; MRSA, methicillin-resistant Staphylococcus aureus; NA, not
assigned; OCC, other clonal complex proﬁle; ST, sequence type.
aResults are in the order 16S, nuc, mecA, arcC210, tpi241 + 243, arcC162,
gmk318, pta294, tpi36, pta383, pvl, cna, sdrE, pUB110, pT181, and aroE252.
bNot assigned to a particular CC or ST.
CMI Syrmis et al. Comparison of MassARRAY and real-time PCR for typing MRSA 1807
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 1804–1810
The 54 incorrect/failed results included failure to detect
nuc (15 instances), sdrE (12 instances), and various SNPs (27
instances). The basis for these discrepancies was further
investigated by DNA sequencing, and the results are summa-
rized in Table 5. Brieﬂy, a failure to amplify or extend
because of sequence variation or deletion in the MRSA-iPLEX
primer targets accounted for the majority of incorrect/failed
results.
Discussion
Epidemiological surveillance of MRSA, which is one of the
most important nosocomial pathogens worldwide, is typically
performed with techniques that have high discriminatory
power but are limited by expense and prolonged result turn-
around times (6,9). Ideal bacterial genotyping systems should
be highly accurate, speciﬁc, fast, reproducible, inexpensive,
and simple, and have a high level of throughput and multi-
plexing capabilities (11,12,20). Recently, Huygens et al. (12)
created a simple SYBR Green-based real-time PCR system
for MRSA typing. Although not as discriminatory as MLST
and PFGE, the system could readily be used to differentiate
important Australian and certain international STs and CCs,
including the Queensland clone ST93, and was easier and
cheaper to perform. However, one limitation of this system
was that it utilized 17 monoplex PCR reactions per isolate,
and was therefore laborious to perform. This may not pres-
ent a problem for laboratories running small batches of iso-
lates, but is particularly cumbersome for large-scale
investigations. The development of post-genomic PCR tech-
nology such as MALDI-TOF MS combined with iPLEX GOLD
chemistry has facilitated higher-throughput analysis of SNPs
(20,21). This technology provides similar simplicity in design
as real-time PCR systems, but enables multiplexing of up to
40 SNPs in a single reaction (21). In this study, we success-
fully multiplexed the original 16 MRSA targets into the
MRSA-iPLEX system, and found that the system provided
optimal throughput for MRSA genotyping for a diverse range
of local and international isolates, and was, on a reagent
basis, considerably less expensive than use of the monoplex
SYBR Green real-time PCR reactions. The MRSA-iPLEX
result turn-around time for complete proﬁles for all 16
markers for all 147 isolates, including duplicates, was <12 h,
at a consumable cost of $AUD5.26 per sample. Results were
obtained in three working days with SYBR Green real-time
PCR, at a cost of $AUD18.00 per sample. The cost beneﬁts
of using MALDI-TOF MS technology for multiplex SNP
detection will probably improve in the foreseeable future as
the costs of the MALDI-TOF MS instrumentation decrease,
making the technology more accessible to the routine clinical
laboratory.
The error rate of MRSA-iPLEX was determined to be
2.3%, and seems to pose a technical limitation. However, the
majority of these errors were limited to particular SNP–
binary groups, suggesting that these issues are probably
related to the sequence composition of certain MRSA types.
DNA sequencing conﬁrmed that the majority of these prob-
lems were caused by sequence variation in the MRSA-iPLEX
targets. In the design of MRSA-iPLEX, many of the MRSA-
iPLEX primer targets were no longer shared with those of
the original real-time PCR assays, being moved either
upstream, downstream, or to the opposite DNA strand.
Changing the primer targets may have been a problem for
certain genes, particularly nuc and sdrE, resulting in primers
being moved away from well-conserved targets. However,
the observed errors are not considered to be a major limita-
tion affecting the utility of MRSA-iPLEX, given that: (i) 36 of
the observed 54 incorrect calls were limited to only six iso-
lates, and these isolates did not belong to clinically signiﬁcant
CCs or STs; and (ii) 15 errors related to nuc, which is
merely used for conﬁrmation of S. aureus DNA and does not
affect the genotype. Redesigning MRSA-iPLEX to accommo-
date sequence variants, new emerging clones or use in
TABLE 5. Sequence analysis of erroneous MRSA-iPLEX results (shown in bold italics)
SYBR Green real-time
PCR proﬁle MRSA-iPLEX proﬁle
No. of
isolates Sequence analysis
111CGATACCA00101 111CGATACCA00001T 1 Deletion in sdrE primer target (primary PCR)
111CGGATCCA01100 111CGGATCCA01000A 1 ND
111TGAAACCA01110 101TGAAACCA01110T 2 ND
111TGATAACT00100 111TGATAACT00000T 3 Deletion in sdrE primer target (primary PCR)
111TGATACCA00100 111TGATACA00100T 1 Single base mismatch in 3¢-end of tpi36 extension primer
111TGGATCCA01000 111TATCCA01000T 1 Single base mismatch in 3¢-end of tpi241/3 extension primer
111TGGTTCCA00100 101GGTA00000T 6 Variations in arcC210, arcC162, tpi36, nuc and sdrE primer
targets (primary PCR); single base mismatch in 3¢-end of
pta294 extension primer
111TGGTTCTA01100 111TGGTTCTA01000A 1 Deletion in sdrE primer target (primary PCR)
111TGGTTCTA10100G 101TGGTTCTA10100G 7 Variations in nuc primer targets (primary PCR)
MRSA, methicillin-resistant Staphylococcus aureus; ND, not detected—variations not observed in respective primer targets.
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different epidemiological contexts is possible by changing the
affected primer set. Such a change could potentially, but not
necessarily, impact on other primers used in the multiplex, so
the resulting multiplex would need to go through a brief revali-
dation procedure on a control sample cohort to establish the
performance of all assays in the multiplex. Redesign of the
monoplex SYBR Green real-time PCR assays would involve a
similar validation procedure, with an advantage being that only
the individual assay in question needs to be considered.
In conclusion, the iPLEX GOLD is a highly useful technol-
ogy as an alternative for SYBR Green-based real-time PCR
typing of SNPs and binary markers of major Australian and
certain international MRSA clones. This assay would be suit-
able for large-scale investigations in research or clinical ﬁelds.
Notwithstanding the results of this study, MRSA-iPLEX
would require evaluation against established MRSA typing
schemes prior to use in different epidemiological contexts.
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